NZ304906A - Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections - Google Patents

Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections

Info

Publication number
NZ304906A
NZ304906A NZ304906A NZ30490696A NZ304906A NZ 304906 A NZ304906 A NZ 304906A NZ 304906 A NZ304906 A NZ 304906A NZ 30490696 A NZ30490696 A NZ 30490696A NZ 304906 A NZ304906 A NZ 304906A
Authority
NZ
New Zealand
Prior art keywords
fumagillol
fight
ester
intestinal infections
optionally saturated
Prior art date
Application number
NZ304906A
Other languages
English (en)
Inventor
Jean-Michel Molina
Francis Derouin
Original Assignee
Sanofi Sa
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Assist Publ Hopitaux De Paris filed Critical Sanofi Sa
Publication of NZ304906A publication Critical patent/NZ304906A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ304906A 1995-03-27 1996-03-26 Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections NZ304906A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (1)

Publication Number Publication Date
NZ304906A true NZ304906A (en) 1999-06-29

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ304906A NZ304906A (en) 1995-03-27 1996-03-26 Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections

Country Status (25)

Country Link
US (1) US5900431A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0817626B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3260378B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100286920B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1072485C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP646A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE172641T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU706161B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2216623C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ286821B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69600879T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0817626T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA000150B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2128846T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR06C0014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU224028B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2048B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO315968B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ304906A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA10515A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL183378B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK283883B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199701048T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA41446C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996030010A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ES2286998T3 (es) * 1999-02-26 2007-12-16 Sanofi-Aventis Formulacion estable que contiene fumagillina.
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
JP5557746B2 (ja) * 2007-11-28 2014-07-23 メルサナ セラピューティックス,インク. 生体適合性生分解性フマギリンアナログ複合体
WO2010009374A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
CA2786603C (en) 2010-01-08 2018-02-20 James E. Vath Fumagillol type compounds and methods of making and using same
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US9173865B2 (en) 2010-11-29 2015-11-03 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9328082B2 (en) 2011-03-08 2016-05-03 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
KR20140040739A (ko) 2011-05-06 2014-04-03 자프겐 인크. 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
CA2861390A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2804856B1 (en) 2012-01-18 2017-03-15 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
WO2013169857A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
WO2014071368A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Methods of treating liver diseases
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
MX2015005732A (es) 2012-11-05 2015-12-16 Zafgen Inc Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
EP2968250B1 (en) 2013-03-14 2019-06-19 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
IS2048B (is) 2005-09-15
FR06C0014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-12-29
CZ286821B6 (en) 2000-07-12
EA199700267A1 (ru) 1998-04-30
WO1996030010A3 (fr) 1996-11-28
WO1996030010A2 (fr) 1996-10-03
ES2128846T3 (es) 1999-05-16
CA2216623A1 (en) 1996-10-03
CN1072485C (zh) 2001-10-10
DE69600879D1 (de) 1998-12-03
CN1179715A (zh) 1998-04-22
KR19980703271A (ko) 1998-10-15
ATE172641T1 (de) 1998-11-15
US5900431A (en) 1999-05-04
HUP9801220A2 (hu) 1999-09-28
TR199701048T1 (xx) 1998-01-21
DK0817626T3 (da) 1999-07-12
SK283883B6 (sk) 2004-04-06
HU224028B1 (hu) 2005-05-30
AU706161B2 (en) 1999-06-10
DE69600879T2 (de) 1999-06-02
OA10515A (fr) 2002-04-24
KR100286920B1 (ko) 2001-04-16
CZ304997A3 (en) 1997-12-17
FR06C0014I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-11-17
PL322470A1 (en) 1998-02-02
MX9707150A (es) 1998-07-31
EA000150B1 (ru) 1998-10-29
JPH11506421A (ja) 1999-06-08
EP0817626A2 (fr) 1998-01-14
SK130797A3 (en) 1998-03-04
NO974466L (no) 1997-09-26
AP646A (en) 1998-04-27
NO974466D0 (no) 1997-09-26
JP3260378B2 (ja) 2002-02-25
CA2216623C (en) 2005-05-31
EP0817626B1 (fr) 1998-10-28
AU5278696A (en) 1996-10-16
PL183378B1 (pl) 2002-06-28
IS4557A (is) 1997-09-11
AP9701092A0 (en) 1997-10-31
UA41446C2 (uk) 2001-09-17
HUP9801220A3 (en) 2001-10-29
NO315968B1 (no) 2003-11-24

Similar Documents

Publication Publication Date Title
NZ304906A (en) Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
BR9405802A (pt) Composição de éster epoxídico
PT871625E (pt) Preparacao de triazoles por adicao organometalica a cetonas e intermediarios destas
PT1066828E (pt) Composicao de aerossol
FI970298A7 (fi) DHA:n käyttö farmaseuttisena koostumuksena
HU9300536D0 (en) Compounds of medical effect
ZA915024B (en) Purification of aqueous liquor
GB2254612B (en) Conversion of ginkgolide C to ginkgolide B
GB2244055B (en) Resolution of glycidic acid derivatives
DE59404990D1 (de) Fettsäureester von Methylglucosid-Derivaten
PL322002A1 (en) Variants of human dnase i
SI0744399T1 (en) Conversion of substituted 8-chloroquinolines to substituted 8-hydroxyquinolines
GB9009916D0 (en) Preparation of acrylic acid derivatives
EP0728008A4 (en) ADMINISTRATION OF TRACE ELEMENTS TO ANIMALS
MX9101029A (es) Oxidacion de poliaromaticos dialquilicos a dicarboxi-poliaromaticos
PL323141A1 (en) Esters of crabapenemes
FI955702L (fi) Syklopropaaniestereiden valmistus
BR9301967A (pt) Aromatizador de ambientes
HU9300076V0 (en) Ball-moving by means of mqgnet to gain points
GB9103814D0 (en) Improvements relating to sound devices
GB8818710D0 (en) Application of adhesive to elongate members
GB9525144D0 (en) Purification of esters
GB9200568D0 (en) Preparation of an artefact
GB9326603D0 (en) Improvements to medical supports
NZ321230A (en) Oxygen conserving device which provides pulse of oxygen to a patient

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired